Asset: Oral small-molecule PD-L1 inhibitor
Development Stage: Preclinical
Indication: Multiple solid tumors
Key Asset Highlights:
1. Demonstrates prominent best-in-class (BIC) potential among oral PD-L1 small-molecule candidates.
2. Exhibits comparable or superior anti-tumor activity to clinical PD-L1 antibody drugs, with potent efficacy in antibody-resistant tumor models.
3. Shows robust synergistic anti-tumor effects in combination with chemotherapy, KRAS inhibitors and VEGF pathway inhibitors, supporting versatile oral combination regimens.
4. Features favorable oral pharmacokinetic properties and a wide safety window, enabling convenient outpatient and home-based administration compared with injectable antibody therapeutics.
5. Protected by a solid and comprehensive intellectual property (IP) portfolio, ensuring stable and exclusive development and commercialization rights.
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
